Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Performance of a tissue-free, molecular residual disease assay in colorectal, breast, and lung cancers from circulating tumor DNA.

Princy Parsana, Garima Kushwaha, Tzu-Chun Chen et al. Jun 01, 2026 pp. 3042-3042 10.1200/jco.2026.44.16_suppl.3042

3042 Background: The Latitude test is a methylation-based, tissue-free molecular residual disease (MRD) test. In this stud...

Frailty-comorbidity discordance and non-relapse mortality after allogeneic hematopoietic cell transplantation.

Nihar Desai, Tommy Alfaro-Moya, Ivan Pasic et al. Jun 01, 2026 pp. 6552-6552 10.1200/jco.2026.44.16_suppl.6552

6552 Background: Non-relapse mortality (NRM) is a barrier to successful allogeneic hematopoietic cell transplantation (HCT...

Sociodemographic and clinical characteristics of women < 50 years and impact on adjuvant chemotherapy decisions across OncotypeDX RS or unknown OncotypeDX categories. A National Cancer Database (NCDB) analysis.

Nerea Lopetegui-Lia, Yevgeniya Gokun, Ashley Pariser Davenport et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12547

e12547 Background: OncotypeDX recurrence score (RS) provides prognostic and predictive information to guide adjuvant treat...

Patient-level clinical response dynamics in advanced melanoma with anzutresgene autoleucel (anzu-cel), a PRAME-directed T-cell receptor (TCR) T-cell therapy.

Diwakar Davar, Sapna Pradyuman Patel, Leonel Fernando Hernandez-Aya et al. Jun 01, 2026 pp. 9508-9508 10.1200/jco.2026.44.16_suppl.9508

9508 Background: Pts with advanced melanoma frequently experience progressive disease (PD) with limited long-term survival...

Regional trends in pancreatic cancer incidence, mortality, and disability-adjusted life years in Pakistan, 1990-2023.

Asad Jahangir, Muhammad Huzaifa Khalil, Rumman Javed et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16414

e16414 Background: Pancreatic cancer is a highly fatal malignancy with limited therapeutic options due to late-stage diagn...

Clinical presentation, management strategies, and recurrence rates in vulvar intraepithelial neoplasia (VIN) globally: A systematic review.

Elizabeth Corn, Sierra Silverwood, Isabela Anawate et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17649

e17649 Background: Vulvar intraepithelial neoplasia (VIN) is a premalignant condition that lacks FDA-approved therapies or...

Precision or perplexity: Assessment of discordance among different PD-L1 assays in the same specimen in advanced non–small cell lung cancer in a community setting.

Hamza Usman, Salman J. Khan, Madhuri yalamanchili et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14579

e14579 Background: PD-L1 expression guides immunotherapy selection in NSCLC, yet multiple assays are used interchangeably...

SATMM: A systems genetic network analysis–based risk stratification tool validated across the disease trajectory of relapsed/refractory multiple myeloma.

Carl Murie, Praneeth Reddy Sudalagunta, Serdar Turkarslan et al. Jun 01, 2026 pp. 7559-7559 10.1200/jco.2026.44.16_suppl.7559

7559 Background: Precision medicine in multiple myeloma (MM) requires risk stratification tools that account for the patie...

Colorectal cancer detection with a multiomic liquid biopsy: Comparing and combining blood- and stool-based tests.

James Munro Cameron, Peter Mitchell, Edward Parkin et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15641

e15641 Background: Colorectal cancer (CRC) remains one of the leading causes of cancer morbidity and mortality worldwide....

Analysis of eligibility and reporting standards for older patients with hormone receptor–positive, HER2-negative metastatic breast cancer (HR+ MBC) in pivotal phase III clinical trials, 2015-2025.

Sidharth Mahajan, Lawrence Nguyen, Jennifer Audrey Weiss et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13087

e13087 Background: Despite the high burden of breast cancer among older adults, there remains underrepresentation of older...

Real-world experience with lifleucel, tumor selection, and dead-in therapy from a single-institution series.

Theresa Medina Jun 01, 2026 pp. 9536-9536 10.1200/jco.2026.44.16_suppl.9536

9536 Background: Lifileucel is the first approved cellular therapy for persons with metastatic melanoma after upfront trea...

Real-world analysis of epigenomic molecular tumor-type prediction for biliary tract cancer in CUP.

Daniel Hintz, Sheila R. Solomon, Jayati Saha et al. Jun 01, 2026 pp. 4161-4161 10.1200/jco.2026.44.16_suppl.4161

4161 Background: Biliary cancers (BTC) are often diagnosed at advanced stages and can present as metastatic liver tumors,...

Image-only and multimodal AI digital pathology biomarkers to demonstrate risk stratification across standard prostate cancer management strategies.

Xinglei Shen, Rana R. McKay, Yi Ren et al. Jun 01, 2026 pp. 5023-5023 10.1200/jco.2026.44.16_suppl.5023

5023 Background: Reliable risk stratification across standard treatment pathways is essential for the clinical adoption of...

Neighborhood disadvantage and correlation with differences in somatic mutations in a real-world breast cancer cohort.

Jacquelyn Dillon, Xuechun Bai, Yashasvini Sampathkumar et al. Jun 01, 2026 pp. 577-577 10.1200/jco.2026.44.16_suppl.577

577 Background: African compared to European genetic ancestry is associated with lower prevalence of clinically actionable...

A phase II combination study of galunisertib and capecitabine in patients with chemotherapy-resistant colorectal cancer with peritoneal metastases.

Ashwini Kanhailal, Alaa Embaby, Bastiaan Nuijen et al. Jun 01, 2026 pp. 3571-3571 10.1200/jco.2026.44.16_suppl.3571

3571 Background: Transforming growth factor β (TGF-β) plays a dynamic role in cancer biology. It acts as a tumor suppresso...

Development of multiplex digital PCR–based <i>ESR1</i> and <i>PIK3CA</i> mutation assays for therapeutic decision-making in HR+/HER2− breast cancer.

Hyunjin Yun, Seung Joo Lee, JunHo Ko et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13008

e13008 Background: Mutations in ESR1 and PIK3CA are clinically important molecular alterations associated with treatment r...

TCM-based syndrome stratification and biological profiling of cancer-related fatigue: A cross-sectional study and scale validation.

Shanshan Gu, Yun Xu, Xiaoshu Zhu Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24137

e24137 Background: Cancer-related fatigue (CRF) is a prevalent symptom with limited interventions. Traditional Chinese Med...

Venous thromboembolism as a trigger for acute cardiac decompensation during cancer hospitalizations: A National Inpatient Sample analysis, 2018–2022.

Christopher Aboujaoude, Sharnvir Chattha, Boone Singtong et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23099

e23099 Background: Venous thromboembolism (VTE) is a common complication of malignancy, but its role as a trigger for acut...

Efficacy and safety of pralsetinib in <i>RET</i> fusion–positive solid tumors: Data from the TAPISTRY trial.

Chia-Chi Lin, Hidetoshi Hayashi, Jee Hyun Kim et al. Jun 01, 2026 pp. 3144-3144 10.1200/jco.2026.44.16_suppl.3144

3144 Background: Pralsetinib is an oral tyrosine kinase inhibitor that selectively and potently targets oncogenic RET fusi...

Traditional Chinese medicine (TCM) for prevention and management of anti-EGFR monoclonal antibody (mAb)–induced cutaneous adverse reactions in patients with metastatic colorectal cancer (mCRC): A retrospective analysis.

Jiani Shi, Haitao Jiang, Jian Yuan et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15584

e15584 Background: Anti-EGFR mAb have significantly improved clinical outcomes in mCRC by inhibiting the EGFR signaling pa...

Adverse effects associated with immune checkpoint inhibitors in locally advanced nasopharyngeal carcinoma: A meta-analysis of randomized controlled trials.

Riccesha Hattin, Rishi Kumar Nanda, Abbas Hussain et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18105

e18105 Background: Immune checkpoint inhibitors (ICIs) are increasingly incorporated into curative-intent treatment strate...

SARM1 inhibition to prevent chemotherapy-induced peripheral neuropathy: Translational and early clinical evaluation of SIR2501.

Linping Yu, Qian Wang, Lianzhu Liu et al. Jun 01, 2026 pp. 12148-12148 10.1200/jco.2026.44.16_suppl.12148

12148 Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common, cumulative, and often irreversible toxici...

Mortality from myocardial infarction in GI malignancy from 1999 to 2020.

Nasir Asif, Riya Tandra, Anirudh Rao et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16332

e16332 Background: Cancer patients are at higher risk of myocardial infarction. Malignancy creates conditions that increas...

A clinically deployable deep learning model for decision support and specimen triage in colorectal histopathology with international pathologist validation.

Sarveswar Chinnaswamy Dhandapani, Elangovan Krishnan, Jansi Rani Sethuraj et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15514

e15514 Background: Colorectal cancer is a leading cause of cancer-related mortality globally, with histopathology as the d...

Shifting demographics and cancer incidence projections in the United States.

Maria Elena Martinez, Alison J. Canchola, Katherine Lin et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22618

e22618 Background: Over the last four decades, racial and ethnic diversity in the United States has increased substantiall...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page